IP Library › Patent Application 15865434
Patent Application
App. No. 15/865,434

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/865,434
Abstract

The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

Claims (411)

1 . An aromatic-cationic peptide selected from the group consisting of:

6-Butyric acid CoQ0-Phe-D-Arg-Phe-Lys-NH 2

6-Decanoic acid CoQ0-Phe-D-Arg-Phe-Lys-NH 2

Arg-Arg-Dmt-Phe

Arg-Cha-Lys

Arg-Dmt

Arg-Dmt-Arg

Arg-Dmt-Lys

Arg-Dmt-Lys-Phe

Arg-Dmt-Lys-Phe-Cys

Arg-Dmt-Phe

Arg-Dmt-Phe-Lys

Arg-Lys-Dmt-Phe

Arg-Lys-Phe-Dmt

Arg-Phe-Dmt-Lys

Arg-Phe-Lys

Arg-Trp-Lys

Arg-Tyr-Lys

Arg-Tyr-Lys-Phe

D-Arg-D-Dmt-D-Lys-D-Phe-NH 2

D-Arg-D-Dmt-D-Lys-L-Phe-NH 2

D-Arg-D-Dmt-L-Lys-D-Phe-NH 2

D-Arg-D-Dmt-L-Lys-L-Phe-NH 2

D-Arg-Dmt-D-Lys-NH 2

D-Arg-Dmt-D-Lys-Phe-NH 2

D-Arg-Dmt-Lys-D-Phe-NH 2

D-Arg-Dmt-Lys-NH 2

D-Arg-Dmt-Lys-Phe-Cys

D-Arg-Dmt-NH 2

D-Arg-L-Dmt-D-Lys-D-Phe-NH 2

D-Arg-L-Dmt-D-Lys-L-Phe-NH 2

D-Arg-L-Dmt-L-Lys-D-Phe-NH 2

D-Arg-Phe-Lys-NH 2

D-Arg-Trp-Lys-NH 2

D-Arg-Tyr-Lys-NH 2

Dmt-Arg

Dmt-Lys

Dmt-Lys-D-Phe-NH 2

Dmt-Lys-NH 2

Dmt-Lys-Phe

Dmt-Lys-Phe

Dmt-Lys-Phe-NH 2

Dmt-Phe-Arg-Lys

H-Arg-D-Dmt-Arg-NH 2

H-Arg-D-Dmt-Lys-NH 2

H-Arg-D-Dmt-Lys-Phe-NH 2

H-Arg-D-Dmt-NH 2

H-Arg-Dmt-Lys-Phe-NH 2

H-D-Arg-2,6-dichloro-L-tyrosine-L-Lys-L-Phe-NH 2

H-D-Arg-2,6-dichlorotyrosine-Lys-Phe-NH 2

H-D-Arg-2,6-difluoro-L-tyrosine-L-Lys-L-Phe-NH 2

H-D-Arg-2,6-difluorotyrosine-Lys-Phe-NH 2

H-D-Arg-2,6-dimethyl-L-phenylalanine-L-Lys-L-Phe-NH 2

H-D-Arg-2,6-dimethylphenylalanine-Lys-Phe-NH 2

H-D-Arg-4-methoxy-2,6-dimethyl-L-tyrosine-L-Lys-L-Phe-NH 2

H-D-Arg-4-methoxy-2,6-dimethyltyrosine-Lys-Phe-NH 2

H-D-Arg-Arg-Dmt-Phe-NH 2

H-D-Arg-Cha-Lys-NH 2

H-D-Arg-D-Dmt-D-Lys-D-Phe-NH 2

H-D-Arg-D-Dmt-Lys-Phe-NH 2

H-D-Arg-D-Dmt-NH 2

H-D-Arg-Dmt-D-Lys-D-Phe-NH 2

H-D-Arg-Dmt-Lys-2,6-dimethylphenylalanine-NH 2

H-D-Arg-Dmt-Lys-3-hydroxyphenylalanine-NH 2

H-D-Arg-Dmt-Lys-NH 2

H-D-Arg-Dmt-Lys-OH

H-D-Arg-Dmt-Lys-Phe-OH

H-D-Arg-Dmt-N6-acetyllysine-Phe-NH 2

H-D-Arg-Dmt-OH

H-D-Arg-Dmt-Phe-Lys-NH 2

H-D-Arg-Dmt-Phe-NH 2

H-D-Arg-D-Phe-L-Lys-L-Phe-NH 2

H-D-Arg-D-Trp-L-Lys-L-Phe-NH 2

H-D-Arg-D-Tyr-L-Lys-L-Phe-NH 2

H-D-Arg-L-Dmt-L-Lys-2,6-dimethyl-L-phenylalanine-NH 2

H-D-Arg-L-Dmt-L-Lys-3-hydroxy-L-phenylalanine-NH 2

H-D-Arg-L-Dmt-L-Lys-D-Dmt-NH 2

H-D-Arg-L-Dmt-L-Lys-D-Trp-NH 2

H-D-Arg-L-Dmt-L-Lys-D-Tyr-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Dmt-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Dmt-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Trp-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Tyr-NH 2

H-D-Arg-L-Dmt-L-Phe-L-Lys-NH 2

H-D-Arg-L-Dmt-N6-acetyl-L-lysine-L-Phe-NH 2

H-D-Arg-L-Lys-L-Dmt-L-Phe-NH 2

H-D-Arg-L-Lys-L-Phe-L-Dmt-NH 2

H-D-Arg-L-Phe-L-Dmt-L-Lys-NH 2

H-D-Arg-L-Phe-L-Lys-L-Dmt-NH 2

H-D-Arg-L-Phe-L-Lys-L-Phe-NH 2

H-D-Arg-L-Trp-L-Lys-L-Phe-NH 2

H-D-Arg-L-Tyr-L-Lys-L-Phe-NH 2

H-D-Arg-Lys-Dmt-Phe-NH 2

H-D-Arg-Lys-Phe-Dmt-NH 2

H-D-Arg-Phe-Dmt-Lys-NH 2

H-D-Arg-Phe-Lys-Dmt-NH 2

H-D-Arg-Tyr-Lys-Phe-NH 2

H-D-Dmt-Arg-NH 2

H-D-His-L-Dmt-L-Lys-L-Phe-NH 2

H-D-Lys-L-Dmt-L-Lys-L-Phe-NH 2

H-Dmt-D-Arg-Lys-Phe-NH 2

H-Dmt-D-Arg-NH 2

H-Dmt-D-Arg-Phe-Lys-NH 2

H-Dmt-D-Phe-Arg-Lys-NH 2

H-Dmt-Lys-D-Arg-Phe-NH 2

H-Dmt-Lys-Phe-D-Arg-NH 2

H-Dmt-Phe-D-Arg-Lys-NH 2

H-Dmt-Phe-Lys-D-Arg-NH 2

H-D-N2-acetylarginine-Dmt-Lys-Phe-NH 2

H-D-N8-acetylarginine-Dmt-Lys-Phe-NH 2

H-D-Phe-D-Arg-D-Phe-D-Lys-NH 2

H-L-Dmt-D-Arg-L-Lys-L-Phe-NH 2

H-L-Dmt-D-Arg-L-Phe-L-Lys-NH 2

H-L-Dmt-L-Lys-D-Arg-L-Phe-NH 2

H-L-Dmt-L-Lys-L-Phe-D-Arg-NH 2

H-L-Dmt-L-Phe-D-Arg-L-Lys-NH 2

H-L-Dmt-L-Phe-L-Lys-D-Arg-NH 2

H-L-His-L-Dmt-L-Lys-L-Phe-NH 2

H-L-Lys-D-Arg-L-Dmt-L-Phe-NH 2

H-L-Lys-D-Arg-L-Phe-L-Dmt-NH 2

H-L-Lys-L-Dmt-D-Arg-L-Phe-NH 2

H-L-Lys-L-Dmt-L-Lys-L-Phe-NH 2

H-L-Lys-L-Dmt-L-Phe-D-Arg-NH 2

H-L-Lys-L-Phe-D-Arg-L-Dmt-NH 2

H-L-Lys-L-Phe-L-Dmt-D-Arg-NH 2

H-L-Phe-D-Arg-L-Dmt-L-Lys-NH 2

H-L-Phe-D-Arg-L-Lys-L-Dmt-NH 2

H-L-Phe-L-Dmt-D-Arg-L-Lys-NH 2

H-L-Phe-L-Dmt-L-Lys-D-Arg-NH 2

H-L-Phe-L-Lys-D-Arg-L-Dmt-NH 2

H-L-Phe-L-Lys-L-Dmt-D-Arg-NH 2

H-Lys-D-Arg-Dmt-Phe-NH 2

H-Lys-D-Arg-Phe-Dmt-NH 2

H-Lys-Dmt-D-Arg-Phe-NH 2

H-Lys-Dmt-Phe-D-Arg-NH 2

H-Lys-D-Phe-Arg-Dmt-NH 2

H-Lys-Phe-D-Arg-Dmt-NH 2

H-Lys-Phe-Dmt-D-Arg-NH 2

H-N2-acetyl-D-arginine-L-Dmt-L-Lys-L-Phe-NH 2

H-N7-acetyl-D-arginine-Dmt-Lys-Phe-NH 2

H-Phe(d5)-D-Arg-Phe(d5)-Lys-NH 2

H-Phe-Arg-Phe-Lys-NH 2

H-Phe-D-Arg-Dmt-Lys-NH 2

H-Phe-D-Arg-Dmt-Lys-NH 2

H-Phe-D-Arg-D-Phe-Lys-NH 2

H-Phe-D-Arg-Lys-Dmt-NH 2

H-Phe-D-Arg-Phe-D-Lys-NH 2

H-Phe-D-Arg-Phe-Lys-Glu-Cys-Gly-NH 2

H-Phe-D-Dmt-Arg-Lys-NH 2

H-Phe-Dmt-D-Arg-Lys-NH 2

H-Phe-Dmt-Lys-D-Arg-NH 2

H-Phe-Lys-D-Arg-Dmt-NH 2

H-Phe-Lys-Dmt-D-Arg-NH 2

L-Arg-D-Dmt-D-Lys-D-Phe-NH 2

L-Arg-D-Dmt-D-Lys-D-Phe-NH 2

L-Arg-D-Dmt-D-Lys-L-Phe-NH 2

L-Arg-D-Dmt-D-Lys-L-Phe-NH 2

L-Arg-D-Dmt-L-Lys-D-Phe-NH 2

L-Arg-D-Dmt-L-Lys-D-Phe-NH 2

L-Arg-D-Dmt-L-Lys-L-Phe-NH 2

L-Arg-D-Dmt-L-Lys-L-Phe-NH 2

L-Arg-L-Dmt-D-Lys-D-Phe-NH 2

L-Arg-L-Dmt-D-Lys-D-Phe-NH 2

L-Arg-L-Dmt-D-Lys-L-Phe-NH 2

L-Arg-L-Dmt-D-Lys-L-Phe-NH 2

L-Arg-L-Dmt-L-Lys-D-Phe-NH 2

L-Arg-L-Dmt-L-Lys-D-Phe-NH 2

L-Arg-L-Dmt-L-Lys-L-Phe-NH 2

L-Arg-L-Dmt-L-Lys-L-Phe-NH 2

Lys-Dmt-Arf

Lys-Dmt-D-Arg-NH 2

Lys-Phe

Lys-Phe-Arg-Dmt

Lys-Phe-NH 2

Lys-Trp-Arg

Lys-Trp-D-Arg-NH 2

Phe-Arg-Dmt-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys-Glu-Cys-Gly

Phe-Dmt-Arg-Lys

Phe-Lys-Dmt

Phe-Lys-Dmt-NH 2

Succinic monoester CoQ0-Phe-D-Arg-Phe-Lys-NH 2

2 . A pharmaceutical composition comprising one or more aromatic-cationic peptides of claim 1 and pharmaceutically acceptable salts thereof.

3 . The pharmaceutical composition of claim 2 further comprising a pharmaceutically acceptable carrier.

4 . A method of reducing the number of mitochondria undergoing mitochondrial permeability transition (MPT), or preventing mitochondrial permeability transitioning in a mammal in need thereof, the method comprising administering to the mammal an effective amount of one or more aromatic-cationic peptides of claim 1 .

5 . A method for reducing oxidative damage in a mammal in need thereof, the method comprising administering to the mammal an effective amount of one or more aromatic-cationic peptides of claim 1 .

6 . A method for increasing the ATP synthesis rate in a mammal in need thereof, the method comprising administering to the mammal an effective amount of one or more aromatic-cationic peptides of claim 1 .

7 . A method for determining the presence or amount of an administered aromatic-cationic peptide in a subject, the method comprising: detecting the administered aromatic-cationic peptide in a biological sample from the subject, wherein the aromatic-cationic peptide is selected from the group consisting of:

6-Butyric acid CoQ0-Phe-D-Arg-Phe-Lys-NH 2

6-Decanoic acid CoQ0-Phe-D-Arg-Phe-Lys-NH 2

Arg-Arg-Dmt-Phe

Arg-Cha-Lys

Arg-Dmt

Arg-Dmt-Arg

Arg-Dmt-Lys

Arg-Dmt-Lys-Phe

Arg-Dmt-Lys-Phe-Cys

Arg-Dmt-Phe

Arg-Dmt-Phe-Lys

Arg-Lys-Dmt-Phe

Arg-Lys-Phe-Dmt

Arg-Phe-Dmt-Lys

Arg-Phe-Lys

Arg-Trp-Lys

Arg-Tyr-Lys

Arg-Tyr-Lys-Phe

D-Arg-D-Dmt-D-Lys-D-Phe-NH 2

D-Arg-D-Dmt-D-Lys-L-Phe-NH 2

D-Arg-D-Dmt-L-Lys-D-Phe-NH 2

D-Arg-D-Dmt-L-Lys-L-Phe-NH 2

D-Arg-Dmt-D-Lys-NH 2

D-Arg-Dmt-D-Lys-Phe-NH 2

D-Arg-Dmt-Lys-D-Phe-NH 2

D-Arg-Dmt-Lys-NH 2

D-Arg-Dmt-Lys-Phe-Cys

D-Arg-Dmt-NH 2

D-Arg-L-Dmt-D-Lys-D-Phe-NH 2

D-Arg-L-Dmt-D-Lys-L-Phe-NH 2

D-Arg-L-Dmt-L-Lys-D-Phe-NH 2

D-Arg-Phe-Lys-NH 2

D-Arg-Trp-Lys-NH 2

D-Arg-Tyr-Lys-NH 2

Dmt-Arg

Dmt-Lys

Dmt-Lys-D-Phe-NH 2

Dmt-Lys-NH 2

Dmt-Lys-Phe

Dmt-Lys-Phe

Dmt-Lys-Phe-NH 2

Dmt-Phe-Arg-Lys

H-Arg-D-Dmt-Arg-NH 2

H-Arg-D-Dmt-Lys-NH 2

H-Arg-D-Dmt-Lys-Phe-NH 2

H-Arg-D-Dmt-NH 2

H-Arg-Dmt-Lys-Phe-NH 2

H-D-Arg-2,6-dichloro-L-tyrosine-L-Lys-L-Phe-NH 2

H-D-Arg-2,6-dichlorotyrosine-Lys-Phe-NH 2

H-D-Arg-2,6-difluoro-L-tyrosine-L-Lys-L-Phe-NH 2

H-D-Arg-2,6-difluorotyrosine-Lys-Phe-NH 2

H-D-Arg-2,6-dimethyl-L-phenylalanine-L-Lys-L-Phe-NH 2

H-D-Arg-2,6-dimethylphenylalanine-Lys-Phe-NH 2

H-D-Arg-4-methoxy-2,6-dimethyl-L-tyrosine-L-Lys-L-Phe-NH 2

H-D-Arg-4-methoxy-2,6-dimethyltyrosine-Lys-Phe-NH 2

H-D-Arg-Arg-Dmt-Phe-NH 2

H-D-Arg-Cha-Lys-NH 2

H-D-Arg-D-Dmt-D-Lys-D-Phe-NH 2

H-D-Arg-D-Dmt-Lys-Phe-NH 2

H-D-Arg-D-Dmt-NH 2

H-D-Arg-Dmt-D-Lys-D-Phe-NH 2

H-D-Arg-Dmt-Lys-2,6-dimethylphenylalanine-NH 2

H-D-Arg-Dmt-Lys-3-hydroxyphenylalanine-NH 2

H-D-Arg-Dmt-Lys-NH 2

H-D-Arg-Dmt-Lys-OH

H-D-Arg-Dmt-Lys-Phe-OH

H-D-Arg-Dmt-N6-acetyllysine-Phe-NH 2

H-D-Arg-Dmt-OH

H-D-Arg-Dmt-Phe-Lys-NH 2

H-D-Arg-Dmt-Phe-NH 2

H-D-Arg-D-Phe-L-Lys-L-Phe-NH 2

H-D-Arg-D-Trp-L-Lys-L-Phe-NH 2

H-D-Arg-D-Tyr-L-Lys-L-Phe-NH 2

H-D-Arg-L-Dmt-L-Lys-2,6-dimethyl-L-phenylalanine-NH 2

H-D-Arg-L-Dmt-L-Lys-3-hydroxy-L-phenylalanine-NH 2

H-D-Arg-L-Dmt-L-Lys-D-Dmt-NH 2

H-D-Arg-L-Dmt-L-Lys-D-Trp-NH 2

H-D-Arg-L-Dmt-L-Lys-D-Tyr-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Dmt-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Dmt-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Trp-NH 2

H-D-Arg-L-Dmt-L-Lys-L-Tyr-NH 2

H-D-Arg-L-Dmt-L-Phe-L-Lys-NH 2

H-D-Arg-L-Dmt-N6-acetyl-L-lysine-L-Phe-NH 2

H-D-Arg-L-Lys-L-Dmt-L-Phe-NH 2

H-D-Arg-L-Lys-L-Phe-L-Dmt-NH 2

H-D-Arg-L-Phe-L-Dmt-L-Lys-NH 2

H-D-Arg-L-Phe-L-Lys-L-Dmt-NH 2

H-D-Arg-L-Phe-L-Lys-L-Phe-NH 2

H-D-Arg-L-Trp-L-Lys-L-Phe-NH 2

H-D-Arg-L-Tyr-L-Lys-L-Phe-NH 2

H-D-Arg-Lys-Dmt-Phe-NH 2

H-D-Arg-Lys-Phe-Dmt-NH 2

H-D-Arg-Phe-Dmt-Lys-NH 2

H-D-Arg-Phe-Lys-Dmt-NH 2

H-D-Arg-Tyr-Lys-Phe-NH 2

H-D-Dmt-Arg-NH 2

H-D-His-L-Dmt-L-Lys-L-Phe-NH 2

H-D-Lys-L-Dmt-L-Lys-L-Phe-NH 2

H-Dmt-D-Arg-Lys-Phe-NH 2

H-Dmt-D-Arg-NH 2

H-Dmt-D-Arg-Phe-Lys-NH 2

H-Dmt-D-Phe-Arg-Lys-NH 2

H-Dmt-Lys-D-Arg-Phe-NH 2

H-Dmt-Lys-Phe-D-Arg-NH 2

H-Dmt-Phe-D-Arg-Lys-NH 2

H-Dmt-Phe-Lys-D-Arg-NH 2

H-D-N2-acetylarginine-Dmt-Lys-Phe-NH 2

H-D-N8-acetylarginine-Dmt-Lys-Phe-NH 2

H-D-Phe-D-Arg-D-Phe-D-Lys-NH 2

H-L-Dmt-D-Arg-L-Lys-L-Phe-NH 2

H-L-Dmt-D-Arg-L-Phe-L-Lys-NH 2

H-L-Dmt-L-Lys-D-Arg-L-Phe-NH 2

H-L-Dmt-L-Lys-L-Phe-D-Arg-NH 2

H-L-Dmt-L-Phe-D-Arg-L-Lys-NH 2

H-L-Dmt-L-Phe-L-Lys-D-Arg-NH 2

H-L-His-L-Dmt-L-Lys-L-Phe-NH 2

H-L-Lys-D-Arg-L-Dmt-L-Phe-NH 2

H-L-Lys-D-Arg-L-Phe-L-Dmt-NH 2

H-L-Lys-L-Dmt-D-Arg-L-Phe-NH 2

H-L-Lys-L-Dmt-L-Lys-L-Phe-NH 2

H-L-Lys-L-Dmt-L-Phe-D-Arg-NH 2

H-L-Lys-L-Phe-D-Arg-L-Dmt-NH 2

H-L-Lys-L-Phe-L-Dmt-D-Arg-NH 2

H-L-Phe-D-Arg-L-Dmt-L-Lys-NH 2

H-L-Phe-D-Arg-L-Lys-L-Dmt-NH 2

H-L-Phe-L-Dmt-D-Arg-L-Lys-NH 2

H-L-Phe-L-Dmt-L-Lys-D-Arg-NH 2

H-L-Phe-L-Lys-D-Arg-L-Dmt-NH 2

H-L-Phe-L-Lys-L-Dmt-D-Arg-NH 2

H-Lys-D-Arg-Dmt-Phe-NH 2

H-Lys-D-Arg-Phe-Dmt-NH 2

H-Lys-Dmt-D-Arg-Phe-NH 2

H-Lys-Dmt-Phe-D-Arg-NH 2

H-Lys-D-Phe-Arg-Dmt-NH 2

H-Lys-Phe-D-Arg-Dmt-NH 2

H-Lys-Phe-Dmt-D-Arg-NH 2

H-N2-acetyl-D-arginine-L-Dmt-L-Lys-L-Phe-NH 2

H-N7-acetyl-D-arginine-Dmt-Lys-Phe-NH 2

H-Phe(d5)-D-Arg-Phe(d5)-Lys-NH 2

H-Phe-Arg-Phe-Lys-NH 2

H-Phe-D-Arg-Dmt-Lys-NH 2

H-Phe-D-Arg-Dmt-Lys-NH 2

H-Phe-D-Arg-D-Phe-Lys-NH 2

H-Phe-D-Arg-Lys-Dmt-NH 2

H-Phe-D-Arg-Phe-D-Lys-NH 2

H-Phe-D-Arg-Phe-Lys-Glu-Cys-Gly-NH 2

H-Phe-D-Dmt-Arg-Lys-NH 2

H-Phe-Dmt-D-Arg-Lys-NH 2

H-Phe-Dmt-Lys-D-Arg-NH 2

H-Phe-Lys-D-Arg-Dmt-NH 2

H-Phe-Lys-Dmt-D-Arg-NH 2

L-Arg-D-Dmt-D-Lys-D-Phe-NH 2

L-Arg-D-Dmt-D-Lys-D-Phe-NH 2

L-Arg-D-Dmt-D-Lys-L-Phe-NH 2

L-Arg-D-Dmt-D-Lys-L-Phe-NH 2

L-Arg-D-Dmt-L-Lys-D-Phe-NH 2

L-Arg-D-Dmt-L-Lys-D-Phe-NH 2

L-Arg-D-Dmt-L-Lys-L-Phe-NH 2

L-Arg-D-Dmt-L-Lys-L-Phe-NH 2

L-Arg-L-Dmt-D-Lys-D-Phe-NH 2

L-Arg-L-Dmt-D-Lys-D-Phe-NH 2

L-Arg-L-Dmt-D-Lys-L-Phe-NH 2

L-Arg-L-Dmt-D-Lys-L-Phe-NH 2

L-Arg-L-Dmt-L-Lys-D-Phe-NH 2

L-Arg-L-Dmt-L-Lys-D-Phe-NH 2

L-Arg-L-Dmt-L-Lys-L-Phe-NH 2

L-Arg-L-Dmt-L-Lys-L-Phe-NH 2

Lys-Dmt-Arf

Lys-Dmt-D-Arg-NH 2

Lys-Phe

Lys-Phe-Arg-Dmt

Lys-Phe-NH 2

Lys-Trp-Arg

Lys-Trp-D-Arg-NH 2

Phe-Arg-Dmt-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys

Phe-Arg-Phe-Lys-Glu-Cys-Gly

Phe-Dmt-Arg-Lys

Phe-Lys-Dmt

Phe-Lys-Dmt-NH 2

Succinic monoester CoQ0-Phe-D-Arg-Phe-Lys-NH 2

8 . The method of claim 7 , wherein detecting is performed during administration of the peptide.

9 . The method of claim 7 , wherein detecting is performed after administration of the peptide.

10 . The method of any one of claim 7 , wherein detecting comprises HPLC.

11 . The method of claim 10 , wherein the HPLC comprises reverse phase HPLC.

12 . The method of claim 10 , wherein the HPLC comprises ion exchange HPLC.

13 . The method of claim 7 , wherein detecting comprises mass spectrometry.

14 . The method of claim 7 , wherein the biological sample comprises a fluid.

15 . The method of claim 7 , wherein the biological sample comprises a cell.

16 . The method of claim 7 , wherein the biological sample comprises a tissue.

17 . The method of any one of claims 7 , wherein the biological sample comprises a biopsy.

18 . An aromatic-cationic peptide selected from the group consisting of:

a) an aromatic-cationic peptide comprising formula VII or a stereoisomer thereof

wherein the chiral centers of formula III are defined as H—(R)-Arg-(S)-DMT-(S)-Lys-(S)-Phe-NH 2 , and wherein stereoisomers are described by the formulas R—S—S—S, S—R—R—R, S—S—S—S, R—R—R—R, R—R—S—S, S—S—R—R, S—R—S—S, R—S—R—R, R—S—R—S, S—R—S—R, R—R—S—R, S—S—R—S, R—R—R—S, S—S—S—R, R—S—S—R, and S—R—R—S;

b) an aromatic-cationic peptide comprising formula VII or a constitutional thereof

selected from the group consisting of Arg-Dmt-Lys-Phe-NH 2 , Phe-Dmt-Arg-Lys-NH 2 , Phe-Lys-Dmt-Arg-NH 2 , Dmt-Arg-Lys-Phe-NH 2 , Lys-Dmt-Arg-Phe-NH 2 , Phe-Dmt-Lys-Arg-NH 2 , Arg-Lys-Dmt-Phe-NH 2 , or Arg-Dmt-Phe-Lys-NH 2 ;

c) an aromatic-cationic peptide comprising formula VIII

wherein R is selected from

(i) OMe, and

(ii) H,

d) an aromatic-cationic peptide comprising formula IX

wherein R is selected from

(i) F,

(ii) Cl, and

(iii) H,

e) an aromatic-cationic peptide comprising formula X

wherein R1-R4 are selected from

(i) Ac, (ii) H, (iii) H, (iv) H,

(i) H, (ii) Ac, (iii) H, (iv) H,

(i) H, (ii) H, (iii) Ac, (iv) H, and

(i) H, (ii) H, (iii) H, (iv) OH;

f) an aromatic-cationic peptide comprising formula XI

19 .- 23 . (canceled)

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2021
From: STEALTH BIOTHERAPEUTICS CORP
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 058164/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: WILSON, D. TRAVIS; ANDERSEN, MARC W.; MEAD, ELIZABETH
To: STEALTH PEPTIDES INTERNATIONAL, INC.
Reel/Frame 047785/0663 →
CHANGE OF NAME Recorded Dec 14, 2018
From: STEALTH PEPTIDES INTERNATIONAL, INC.
To: STEALTH BIOTHERAPEUTICS CORP
Reel/Frame 049027/0228 →